The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis

International Journal of Cancer

Volumn 112, Issue 2, 2004, Pages 225-230

  Braumann, Chris ^a   Henke, Wolfgang ^a   Jacobi, Christoph A ^a   Dubiel, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer therapy; Colon adenocarcinoma cell; Protein biosynthesis; Taurolidine; Translation

Indexed keywords

DISINFECTANT AGENT; I KAPPA B ALPHA; MESSENGER RNA; PROTEIN C JUN; PROTEIN P105; PROTEIN P27; PROTEIN P53; PROTEIN SYNTHESIS INHIBITOR; TAUROLIDINE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; BACTERIUM; CANCER INHIBITION; CELL DEATH; COLON ADENOCARCINOMA; CONTROLLED STUDY; DENSITY GRADIENT; DOSE RESPONSE; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; TRANSLATION INITIATION; TUMOR GROWTH;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BACTERIA; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; PROTEIN BIOSYNTHESIS; TAURINE; THIADIAZINES; TRANSCRIPTION FACTORS;

EID: 4544278144     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20393     Document Type: Article

References (33)

1. Jacobi CA, Sabat R, Ordemann J, Wenger F, Volk HD, Müller JM. Peritoneale Instillation von Taurolidin und Heparin zur Verhinderung von intraperitonealem Tumorwachstum und Trokarmetastasen bei laparoskopischen Operationen im Rattenmodell. Langenbecks Arch Chir 1997;382:31-6.
2. Jacobi CA, Wildbrett P, Volk T, Müller JM. Influence of different gases and intraperitoneal instillation of antiadherent or cytotoxic agents on peritoneal tumor cell growth and implantation with laparoscopic surgery in a rat model. Surg Endosc 1999;13:1021-5.
3. Braumann C, Ordemann J, Wildbrett P, Jacobi CA. The influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumor growth in rats. Clin Exp Metastasis 2000;18:547-52.
4. Blenkharn JJ. Sustained anti-adherence activity of taurolidine (Taurolin) and noxythiolin (Noxyflex S). J Pharmacol 1988;40:509-11.
5. Teschner M. Taurolidin in der septischen Chirurgie. Stuttgart: Georg Thieme Verlag, 1996.
6. Billing A, Fröhlich D, Ruckdeschel G. Der Einfluss von Taurolin auf die körpereigene Abwehr und die Keimelimination bei der menschlichen Peritonitis. Langenbecks Arch Chir 1992;377:180-5.
7. Böhm B, Schwenk W, Müller JM. Long-term results after laparoscopic resection of colorectal carcinoma. Chirurg 1998;70:453-5.
8. Knight BI, Skellern GG, Browne MK, Pfirrmann RW. Peritoneal absorption of the antibacterial and antiendotoxin taurolidine in peritonitis. Br J Clin Pharmacol 1981;12:695-9.
9. Perry JD, Riley G, Johnston S, Dark JH, Gould FK. Activity of disinfectants against gram-negative bacilli isolated from patients undergoing lung transplantation for cystic fibrosis. J Heart Lung Transplant 2002;21:1230-1.
10. Bedrosian I, Sofia RD, Wolff SM, Dinarello CA. Taurolidine. An analogue of the amino acid taurine, suppresses interleucin-1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 1991;3:568-75.
11. Yanagisawa M, Imai H, Fukushima Y. Effects on tumor necrosis factor alpha and interleukin 1 beta on the proliferation of cultured glomerular epithelial cells. Virchows Arch 1994;426:581-6.
12. Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J, Calabresi P. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res 2002;22:1959-64.
13. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattrodt M, Brock M. The effect of taurolidine on brain tumor cells. Anticancer Res 2002;22:809-14.
14. Lanfrancone L, Boraschi D, Ghiara P. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor, granulocyte-monocyte CSF, macrophage CSF, IL-1 and IL-2) and are activated and stimulated to grow by IL-1. Blood 1992;80:2835-42.
15. Norrby K. Angiogenesis: new aspects relating to its initiation and control. APMIS 1997;105:417-37.
16. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFα and IL-1α. Int J Cancer 2000;85:182-8.
17. van Antwerp DJ, Martin SJ, Verma IM, Green DR. Inhibition of TNF-induced apoptosis by NFκB. Cell Biol 1998;8:107-11.
18. Maniatis T. Catalysis by a multiprotein IκB kinase complex. Science 1997;278:818-9.
19. Suzuki H, Chiba T, Kobayashi M, Takeuchi M, Furuichi K, Tanaka K. In vivo and in vitro recruitment of an IkappaBalpha-ubiquitin ligase to IkappaBalpha phosphorylated by IKK, leading to ubiquitination. Biochem Biophys Res Commun 1999;256:121-6.
20. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, Pollmann C, Dubiel W. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 2001;20:1630-9.
21. Gray NK. Translational control by repressor proteins binding to the 5′UTR of mRNAs. Methods Mol Biol 1998;77:379-97.
22. Seeger M, Kraft R, Ferrell K, Bech-Otschir D, Dumdey R, Schade R, Gordon C, Naumann M, Dubiel W. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J 1998;12:469-78.
23. Jacobi CA, ed. Taurolidin in der Tumortherapie-Vorstellung eines neuen Therapiekonzeptes, 1st ed. Bremen: UNI-MED Verlag, 2003.
24. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
25. Pioletti M, Schlunzen F, Harms J, Zarivach R, Gluhmann M, Avila H, Bashan A, Bartels H, Auerbach T, Jacobi C, Hartsch T, Yonath A, Franceschi F. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J 2001;20:1829-39.
26. Watkins SJ, Norbury CJ. Translation initiation and its deregulation during tumorigenesis. Br J Cancer 2002;86:1023-7.
27. Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001;61:6816-21.
28. Sah NK, Munshi A, Kurland JF, McDonnell TJ, Su B, Meyn RE. Translation inhibitors sensitize prostate cancer cells to TRAIL-induced apoptosis by activating c-Jun N-terminal kinase. J Biol Chem 2003;278:20593-602.
29. Clemens MJ. Translational regulation in cell stress and apoptosis. Roles of the eIF4E binding proteins. J Cell Mol Med 2001;5:221-39.
30. Li S, Takasu T, Perlman DM, Peterson MS, Burrichter D, Avdulov S, Bitterman PB, Polunovsky VA. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003;278:3015-22.
31. McCourt M, Wang JH, Sookhai S, Redmond HP. Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 2000;7:685-91.
32. Shrayer DP, Lukoff H, King T, Calabresi P. The effect of taurolidine on adherent and floating subpopulations of melanoma cells. Anticancer Drugs 2003;14:295-303.
33. Lon G, Burri C. Perioperative Wundspülung-Vergleich Taurolidin 1% und Nebacetin-Lösung. In: Brückner WL, Pfirrmann RW. Taurolidin-Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. München: Urban & Schwarzenberg, 1985. 136-42.